Wells Fargo Maintains Overweight on Ascendis Pharma, Lowers Price Target to $326
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Wells Fargo analyst Derek Archila maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and lowers the price target from $330 to $326.
Wells Fargo analyst Derek Archila maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and lowers the price target from $330 to $326.